Background: Follow-up of celiac disease (CD) patients is recommended for gluten-free diet (GFD) adherence monitoring and complication detection. We recently showed that 35% of children with CD were lost to follow-up (LTFU). We aimed to characterize LTFU population, and thus identify compliance barriers to GFD and follow-up. Methods: 50 LTFU patients were investigated using a telephone questionnaire, regarding frequency of follow-up, serology testing, and adherence to GFD (using the validated Biagi score). Fifty two regular follow-up patients served as controls. Results: LTFU patients had poor adherence to GFD (average Biagi score of 2.0 ± 1.4) compared to controls (3.0 ± 1.0, p < 0.001). Only 22% of LTFU performed periodic celiac serology testing compared to 82% of controls (p < 0.001). LTFU had higher prevalence of positive celiac serology tests (50% compared to 25% of controls, p = 0.01). Fewer LTFU were National Celiac Association members (24%) compared with controls (44%, p = 0.05). Regression analysis showed positive relationships between LTFU and poor adherence to GFD (R2 = 0.26737, p = 0.001), older age at diagnosis (R2 = 0.30046, p = 0.03), and non-membership in a celiac association (R2 = 0.18591, p = 0.0001). Conclusion: LTFU is associated with non-adherence to GFD and positive serology. Risk factors for LFTU should be identified and addressed in order to improve patient care.

Journal Section:
Original Paper
Keywords:
Celiac disease, GFD, Children, Lost to follow-up, Biagi score
1.
Shamir R, Lerner A, Shinar E, Lahat N, Sobel E, Bar-or R, Kerner H, Eliakim R: The use of a single serological marker underestimates the prevalence of celiac disease in Israel: a study of blood donors. Am J Gastroenterol 2002;97:2589-2594.
[PubMed]
https://doi.org/10.1111/j.1572-0241.2002.06028.x
2.
Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ: The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010;7:204-213.
[PubMed]
https://doi.org/10.1038/nrgastro.2010.23
3.
Pietzak MM: Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 2005;128:135-141.
[PubMed]
https://doi.org/10.1053/j.gastro.2005.02.025
4.
Jadresin O, Misak Z, Sanja K, Sonicki Z, Zizić V: Compliance with gluten-free diet in children with coeliac disease. J Pediatr Gastroenterol Nutr 2008;47:344-348.
[PubMed]
https://doi.org/10.1097/MPG.0b013e31816f856b
5.
Rashid M, Cranney A, Zarkadas M, Graham ID, Switzer C, Case S, Molloy M, Warren RE, Burrows V, Butzner JD: Celiac disease: evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics 2005;116:&#x200B;e754-e759.
[PubMed]
https://doi.org/10.1542/peds.2005-0904
6.
Mustalahti K, Lohiniemi S, Collin P, Vuolteenaho N, Laippala P, Maki M: Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 2002;5:105-113.
[PubMed]
7.
Mozer-Glassberg Y, Zevit N, Rosenbach Y, Hartman C, Morgenstern S, Shamir R: Follow-up of children with celiac disease - lost in translation? Digestion 2011;83:283-287.
[PubMed]
https://doi.org/10.1159/000320714
8.
Biagi F, Bianchi PI, Marchese A, Trotta L, Vattiato C, Balduzzi D, Andrealli A, Cisaro F, Astegiano M, Pellegrino S, Magazzu G, Klersy C, Corazza GR: A score that verifies adherence to a gluten-free diet: a cross-sectional, multicentre validation in real clinical life. Br J Nutr 2012;108:1884-1888.
[PubMed]
https://doi.org/10.1017/S0007114511007367
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.